U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Lawmakers say the drug company has made $50 billion on the sales of those two drugs since 2018. Tuesday, members of the U.S.

CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.